Natural Killer (NK) Cell Therapeutics Market Rising the Growth Leading Key Players | Nkarta, Inc, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Affimed GmbH, Zelluna Immunotherapy, Nektar Therapeutics, XNK Therapeutics AB

Global Natural Killer (NK) Cell Therapeutics Market: Investment & Growth Opportunity Analysis, 2019-2028

Market Introduction:

The Global Natural Killer (NK) Cell Therapeutics market is estimated to grow at a robust CAGR of 51.8% during the forecast period of 2022-2028. The market growth is attributed to the increasing interest of the pharmaceutical industry players in cellular immunotherapy. NK cell therapeutics is anticipated to witness robust growth during the forecast period owing to its ability to fulfil unmet medical needs, overcome limitations associated with existing immunotherapies, and address complex and challenging targets.

Download Free PDF Sample of Natural Killer (NK) Cell Therapeutics Market report @ https://www.themarketinsights.com/request-sample/265163

The recent increase in the number of approvals received for cancer immunotherapies is considered to have added value to the NK cell therapeutic market. Moreover, market players are making efforts for the development of novel NK cell therapies which further gives a boost to the growth of the market. For instance, Under the agreement, Gilead would receive an exclusive, worldwide license from Dragonfly for the 5T4-targeting investigational immunotherapy program, DF7001. DF7001 is a TriNKET designed to activate and direct NK and cytotoxic T cell killing against cancer cells. The target of DF7001 is 5T4, a protein expressed on cancer cells and stromal cells that support tumor growth associated with poor prognosis in several cancers, including non-small cell lung cancer (NSCLC), pancreatic cancer, breast cancer, and head and neck squamous cell carcinomas (HNSCC).

Market Segmentation

The global NK cell therapeutics market has been analyzed on the basis of application, end user, and region. On the basis of application, the market is segmented into Cancer, Gastrointestinal Diseases, Immunoproliferative Disorders, and Others. Cancer segment is expected to dominate the global market. Based on end user, the market is divided into hospitals and research centers & institutes. Geographically, the market is segmented into North America, Latin America, Western Europe, Eastern Europe, Asia Pacific and Middle East & Africa. North America is dominating the global NK cell therapeutics market.

Get Discount @ https://www.themarketinsights.com/check-discount/265163

Market Structure and Competitive Landscape:

Some of the prominent players that contribute significantly to the growth of the global NK cell therapeutics market include Nkarta, Inc, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Affimed GmbH, Zelluna Immunotherapy, Nektar Therapeutics, XNK Therapeutics AB, ONK Therapeutics, Catarman Bio, MiNK Therapeutics, Celularity Inc., Artiva Biotherapeutics and others. These players adopt various strategies to reinforce their market share and gain a competitive edge over other competitors in the market. Partnerships and collaborations, research & development, and product launches are some of the strategies followed by industry players.

Report Customization available as per requirements @ https://www.themarketinsights.com/request-customization/265163

Some of the key developments in the global NK cell therapeutics market include,

1. In August 2022, Zelluna Immunotherapy announced an investment from Takeda Ventures, Inc. (TVI), the strategic investing arm of Takeda. TVI investment joins Zelluna's latest financing round. The funds will enable the advancement of a lead TCR-NK product through manufacturing to Clinical Trial Application (CTA) / Investigational New Drug Application (IND) readiness and, continue the advancement of Zelluna's platform with additional programs reaching the preclinical stage.

2. In January 2022, Takeda announced to acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta, T Cell Engager Therapies Targeting Solid Tumors. Through the acquisition, Takeda would obtain Adaptate's antibody-based, T cell engager platform, including pre-clinical candidate and discovery pipeline programs.

Partial Table of Content:

Chapter One: Market Introduction
1.1. Scope of Study
1.2. Problem Statement
1.3. Market Segmentation

Chapter Two: Assumptions and Acronyms

Chapter Three: Executive Summary
3.1. Global Market in2022
3.2. Analyst Insights & Recommendations
3.3. Growth Opportunities and Key Strategies
3.4. Supply-side and Demand-side Trends

Chapter Four: Research Methodology

Contact us:

Jessica Joyal
+16146022897
Email: sales@themarketinsights.com
Visit our website: www.themarketinsights.com

About:

Delivering foresights along with statistical analysis of the operational business industry impacts has been our foremost priority. With the constant developments in the research & development industry, we have always challenged the conventional research methodologies and discovered new research tactics to evolve the growing B2B requirements.

This release was published on openPR.